Summary
28 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 5.7% a year over the last 3 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 5.7% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $4.75 is 97% above today's price. 0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2027By product
- Fixed-Price Contract 100%
By region
The company reports no revenue by region.
Fixed-Price Contract brings in 100% of revenue.
Segments in detail